432 related articles for article (PubMed ID: 23994369)
1. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout.
Lü JM; Yao Q; Chen C
Biochem Pharmacol; 2013 Nov; 86(9):1328-37. PubMed ID: 23994369
[TBL] [Abstract][Full Text] [Related]
2. A potential therapeutic agent for the treatment of hyperuricemia and gout: 3,4-Dihydroxy-5-nitrobenzaldehyde phenylthiosemicarbazide.
Yu X; Ren S; Zhou J; Liao Y; Huang Y; Dong H
Eur J Pharm Sci; 2024 Jul; 198():106778. PubMed ID: 38653341
[TBL] [Abstract][Full Text] [Related]
3. Antioxidant, antihyperuricemic and xanthine oxidase inhibitory activities of Hyoscyamus reticulatus.
Mohammad MK; Almasri IM; Tawaha K; Issa A; Al-Nadaf A; Hudaib M; Alkhatib HS; Abu-Gharbieh E; Bustanji Y
Pharm Biol; 2010 Dec; 48(12):1376-83. PubMed ID: 20738177
[TBL] [Abstract][Full Text] [Related]
4. Effects of extracts from Corylopsis coreana Uyeki (Hamamelidaceae) flos on xanthine oxidase activity and hyperuricemia.
Yoon IS; Park DH; Ki SH; Cho SS
J Pharm Pharmacol; 2016 Dec; 68(12):1597-1603. PubMed ID: 27696407
[TBL] [Abstract][Full Text] [Related]
5. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen.
Ogura J; Kuwayama K; Sasaki S; Kaneko C; Koizumi T; Yabe K; Tsujimoto T; Takeno R; Takaya A; Kobayashi M; Yamaguchi H; Iseki K
Biochem Pharmacol; 2015 Sep; 97(1):89-98. PubMed ID: 26119820
[TBL] [Abstract][Full Text] [Related]
6. Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice.
Wang SY; Yang CW; Liao JW; Zhen WW; Chu FH; Chang ST
Phytomedicine; 2008 Nov; 15(11):940-5. PubMed ID: 18693097
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and biological evaluation of N-(3-cyano-1H-indol-5/6-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides and 5-(6-oxo-1,6-dihydropyrimidin-2-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Zhang B; Duan Y; Yang Y; Mao Q; Lin F; Gao J; Dai X; Zhang P; Li Q; Li J; Dai R; Wang S
Eur J Med Chem; 2022 Jan; 227():113928. PubMed ID: 34688012
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological basis for use of Pistacia integerrima leaves in hyperuricemia and gout.
Ahmad NS; Farman M; Najmi MH; Mian KB; Hasan A
J Ethnopharmacol; 2008 May; 117(3):478-82. PubMed ID: 18420362
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidase inhibitory activity and antihyperuricemic effect of Moringa oleifera Lam. leaf hydrolysate rich in phenolics and peptides.
Tian Y; Lin L; Zhao M; Peng A; Zhao K
J Ethnopharmacol; 2021 Apr; 270():113808. PubMed ID: 33450289
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of hydroxychalcones as multifunctional non-purine xanthine oxidase inhibitors for the treatment of hyperuricemia.
Xie Z; Luo X; Zou Z; Zhang X; Huang F; Li R; Liao S; Liu Y
Bioorg Med Chem Lett; 2017 Aug; 27(15):3602-3606. PubMed ID: 28655421
[TBL] [Abstract][Full Text] [Related]
11. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).
Ojha R; Singh J; Ojha A; Singh H; Sharma S; Nepali K
Expert Opin Ther Pat; 2017 Mar; 27(3):311-345. PubMed ID: 27841045
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 1-alkyl-5/6-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1H-indole-3-carbonitriles as novel xanthine oxidase inhibitors.
Gao J; Liu X; Zhang B; Mao Q; Zhang Z; Zou Q; Dai X; Wang S
Eur J Med Chem; 2020 Mar; 190():112077. PubMed ID: 32014678
[TBL] [Abstract][Full Text] [Related]
13. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
14. Novel 3-[4-alkoxy-3-(1H-tetrazol-1-yl) phenyl]-1,2,4-oxadiazol-5(4H)-ones as promising xanthine oxidase inhibitors: Design, synthesis and biological evaluation.
Gao J; Zhang Z; Zhang B; Mao Q; Dai X; Zou Q; Lei Y; Feng Y; Wang S
Bioorg Chem; 2020 Jan; 95():103564. PubMed ID: 31927335
[TBL] [Abstract][Full Text] [Related]
15. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
16. Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity.
Niu Y; Liu J; Liu HY; Gao LH; Feng GH; Liu X; Li L
Pharm Biol; 2016 Sep; 54(9):1680-6. PubMed ID: 26916555
[TBL] [Abstract][Full Text] [Related]
17.
Mehmood A; Rehman AU; Ishaq M; Zhao L; Li J; Usman M; Zhao L; Rehman A; Zad OD; Wang C
Comb Chem High Throughput Screen; 2020; 23(9):917-930. PubMed ID: 32342806
[TBL] [Abstract][Full Text] [Related]
18. Impact of Lesinurad and allopurinol on experimental Hyperuricemia in mice: biochemical, molecular and Immunohistochemical study.
Alghamdi YS; Soliman MM; Nassan MA
BMC Pharmacol Toxicol; 2020 Feb; 21(1):10. PubMed ID: 32041665
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, structure-activity relationships, and mechanistic studies of 5-arylazo-tropolone derivatives as novel xanthine oxidase (XO) inhibitors.
Sato D; Kisen T; Kumagai M; Ohta K
Bioorg Med Chem; 2018 Jan; 26(2):536-542. PubMed ID: 29274704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
